Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ERIC CLL 2026 | Deciding between treatment regimens for fit, newly diagnosed patients with CLL

Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the choice of treatment for fit, newly diagnosed patients with chronic lymphocytic leukemia (CLL), favoring time-limited regimens such as acalabrutinib plus venetoclax (AV) for those without TP53 aberrations. Dr Davids highlights the convenience of an all-oral regimen like acalabrutinib plus venetoclax (AV), but also notes the effectiveness of venetoclax plus obinutuzumab (VO), and awaits results from the ongoing Phase III MAJIC trial (NCT05057494) which is comparing these regimens. This interview took place at the 2026 ERIC International Meeting in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

So for my fit younger patients without TP53 aberration, I really try to steer those patients toward a time-limited regimen at this point. They can certainly do well with covalent BTK inhibitors, but especially if they have low genetic risk disease, I think it’s beneficial to have a more intensive period of two or three drugs and then be able to have a long treatment-free interval without the need for continuous therapy...

So for my fit younger patients without TP53 aberration, I really try to steer those patients toward a time-limited regimen at this point. They can certainly do well with covalent BTK inhibitors, but especially if they have low genetic risk disease, I think it’s beneficial to have a more intensive period of two or three drugs and then be able to have a long treatment-free interval without the need for continuous therapy. You know, within the discussion of BTK plus BCL2 versus BCL2 and CD20, that’s a long and nuanced conversation for patients. Obviously, there’s something very attractive about an all-oral regimen like AV, very convenient for patients, particularly when starting, because they start with a couple of months of acalabrutinib alone, which is generally pretty straightforward, and then the venetoclax comes a couple of months in. With venetoclax and obinutuzumab, it starts with the obinutuzumab. So it can be a bit more challenging to get those initial infusions in. But then patients start on the venetoclax and they’re usually well debulked. So I think that’s also a great strategy. And so right now, we really don’t know what strategy would be better for patients, AV or VO? We have an ongoing phase three trial called MAGIC, which is directly comparing those two regimens, and we hope to see data from that soon to really better understand the optimal regimen for each patient.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.